Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells

The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resist...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Matsuda, Yasufumi, Yamauchi, Takahiro, Hosono, Naoko, Uzui, Kanako, Negoro, Eiju, Morinaga, Koji, Nishi, Rie, Yoshida, Akira, Kimura, Shinya, Maekawa, Taira, Ueda, Takanori
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://ncbi.nlm.nih.gov/pubmed/27166836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12965
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky